Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236,…
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement -…
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement -…
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")…